Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 27, 2008

Raynard S. Kington to Serve as NIH Acting Director

  • Raynard S. Kington, M.D., Ph.D., will become acting director of the NIH once Elias Zerhouni, M.D., resigns. Dr. Zerhouni decided about a month ago to leave the institute at the end of this month.

    Dr. Kington previously served as NIH's principal deputy director. He worked closely with the director on the overall leadership, policy direction, and coordination of NIH’s 27 institutes and centers. He has held various positions within the NIH and the CDC and was a senior scientist at Rand.


Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »